8IH
0.049
308.3%
AUH
0.001
-50%
ERA
0.003
50%
TMK
0.001
-50%
MRD
0.025
47.1%
CNJ
0.007
-36.4%
RDN
0.007
40%
LRM
0.027
-28.9%
AUR
0.027
35%
FBR
0.003
-25%
LIB
0.004
33.3%
UNT
0.009
-25%
BEL
0.026
30%
WBE
0.008
-20%
LKO
1.5
28.2%
FRX
0.009
-18.2%
RKB
0.005
25%
NOR
0.018
-18.2%
AR9
0.1
23.5%
YAR
0.009
-18.2%
SCN
0.037
23.3%
KSN
0.115
-17.9%
AS2
0.016
23.1%
PBL
0.095
-17.4%
PVT
0.027
22.7%
COS
0.495
-16.8%
ENL
0.029
20.8%
BLU
0.005
-16.7%
CRN
0.35
20.7%
PGY
0.005
-16.7%
ADG
0.013
18.2%
SIS
0.005
-16.7%
WCN
0.02
17.6%
TAR
0.01
-16.7%
FGH
0.034
17.2%
IPD
0.039
-15.2%
IKE
1.08
16.8%
QEM
0.017
-15%
TNC
0.28
16.7%
LSR
0.029
-14.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Control Bionics (ASX:CBL): Expands global reach with exclusive UK and Ireland distribution agreement

Control Bionics (ASX:CBL) expands global reach with exclusive UK and Ireland distribution agreement.

• Exclusive distribution of NeuroNode® by Smart Box in the UK and Ireland.
• Access to Smart Box’s established network of healthcare professionals and end-users.
• Strengthening Control Bionics’ presence in the European market.

Jeremy Steele, CEO of Control Bionics, commented: “The NeuroNode® has already been paired with hundreds of Smart Box
devices and devices with Smart Box software around the world.”

Read the ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240909/pdf/067np1hzgg2sbv.pdf